|
|
|
3i Initiative Weekly Updates
Welcome to the 3i Weekly Update, your source for 3i relevant news and events. Please send all items of interest to Nicole.Frank@hsc.utah.edu by the end of the day on Thursdays.
| |
|
|
3/26- 4/2- FRIDAY, MARCH 26, 2021, 1 – 2PM - Department of History Annual Wilson Lecture with Professor Adria Imada - "How To Survive An Epidemic and Other Lessons From History"
- MONDAY, MARCH 29 - 4 - 5PM, -Pharmaceutics & Pharmaceutical Chemistry Seminars - Dr. Anjali - “Drug Discovery & Development Journey; Successes, Failures and Lesson Learned”
- MONDAY, MARCH 29 - 4 - 5PM, -Pharmaceutics & Pharmaceutical Chemistry Seminars - Dr. Heather Gustafson - “Macrophage Plasticity: Roles in Immunotherapeutic Success and Failure”
- WEDNESDAY, MARCH 31, 2021, 4:30-5:30 (MST) - Penn INSPIRE - featuring Dr. Keke Fairfax
- WEDNESDAY, MARCH 31, 2021, 5:30 – 7PM - Evening Ethics: "The Ethics of COVID Vaccine Distribution: Who? How? What about Line-Jumpers? And what of Those Who Refuse? "
- MARCH 30-31 - Keith Marmer (PIVOT Center) - Oncology Therapy Development Workshop: Pivotal Steps and Avoiding Pitfalls for Start-ups
- THURSDAY, APRIL 1, 2021, 12 – 1PM - Internal Medicine Grand Rounds - "Screening and Surveillance for Barrett's Esophagus" - Dr. John M. Inadomi
- MONDAY, APRIL 5 – FRIDAY, APRIL 9, 2021 - 2nd Annual Symposium for Underserved, Rural, and Global Education
| |
|
- Open Postdoctoral Research Position - Tumor Immunology - The Department of Internal Medicine, Division of Gastroenterology is seeking a highly motivated Postdoctoral Fellow to study novel immunotherapy approaches for gastrointestinal cancers. Experience with mouse work, flow cytometry, and immune cell assays is preferable. Applicants must have obtained a PhD in cancer biology, immunology, or a related field within the past three years. Strong oral and written English skills are required. The successful candidate should have independent research skills and a track record of success in the laboratory.
Interested applicants please submit a CV and contact information for 3 references to ellen.beswick@hsc.utah.edu
- Open Postdoctoral Research Position - The Puri Lab at the University of Utah seeks to hire a postdoctoral research associate to work on a funded project studying the biosynthesis of natural products made by underexplored bacteria. The ideal candidate will have a Ph.D. in Biochemistry, Chemistry, Microbiology, or a related field, and experience with protein expression, purification, and enzymology. Interested applicants should contact Aaron Puri directly (a.puri@utah.edu) with a cover letter, CV, and contact information for 3 references.
- SEAL (Science Excelerator and Leadership) Program Position Open - With this change in mind, the Gregg lab at the University of Utah is transitioning to a new model of science and discovery that caters to professional scientists by launching the SEAL (Science Excelerator and Leadership) Program. We are investigating new ways to take on higher impact scientific problems and make major advances in a shorter period of time. To help with this, the lab will transition to a new name – the Precision Brain Genetics Lab. This name change reflects the focus of the science and important roles of senior investigators in the lab and their capability to obtain independent grants if they wish. Right now, we are seeking to recruit a new SEAL program scientist to the lab at the level of a career track assistant professor, staff scientist or postdoctoral fellow.
| |
|
|
- Annual Symposium: Sex, Gender and Women’s Health Across the Lifespan - THURSDAY, MAY 13, 2021
- 3i Initiative Spring 2021 Symposium - FRIDAY, ARPIL 30, 2021, 8:00 AM -5:00 PM
- 2021 COVID-19 Symposium - FRIDAY, JUNE 4, 2021, 8:00 AM -5:00 PM
| |
|
- Call for applications: 3i Training Grant - We are pleased to announce that we are accepting applications from graduate students for the Immunology, Infectious Disease and Inflammation (3i) Training Grant (3iTG). The Training Grant will provide support for one year, with the potential to renew for a second year of support. We will be appointing 2 graduate student trainees this year. Some of the features of the training program include support for mentored research, a clinical immunology rotation at ARUP (pandemic permitting), training in data analysis and publishing, grant writing and career planning, mentored preparation and submission of F award proposal or equivalent, yearly presentation of data to the immunology community and partial support for travel to scientific meetings to present research findings. See application instructions here. Applications are due April 12th, 2021
- CCTS Peer Grant Review Program - Now Accepting Research Proposals for Pre-Submission Peer Review - The Utah Center for Clinical and Translational Science (CCTS) is now accepting research proposals for pre-submission peer review. The program accepts proposals from investigators conducting research at any point along the translational science spectrum aiming to improve the health of individuals and the public. Please limit one proposal submission per investigator to the PGR. NIH review criteria will be used to score each submission. Formal reviews will be returned to the investigator by May 3, 2021. Submission Requirements Investigators are required, via email, to submit a) the completed CCTS Peer Grant Review Face Page form (see below or fillable version); b) their NIH Biographical Sketch, Specific Aims, Research Strategy, and Bibliography & References Cited as word documents; and c) any other appropriate ancillary documents as a single PDF (see Guidance Checklists) to Breanne Johnson (Breanne.Johnson@hsc.utah.edu) no later than 4:00 pm on Thursday, April 23rd, 2021.
- Hatch Scholar for T1D Research - Request for Applications - due April 30, 2021 - We are pleased to announce the sixth annual Hatch Family Scholar Award Competition for graduate students and postdoctoral fellows at the University of Utah. The purpose of this award is to honor the Hatch family by rewarding a junior research scientist that is conducting research in the field of Type 1 Diabetes. A minimum prize of $1,000 will be awarded. Prizes are subject to federal tax regulations. Applications and all supporting documents should be compiled as one PDF and submitted electronically through the University of Utah’s Competition Space interface at http://utah.infoready4.com/ by April 30, 2021 at 5pm, search “The Paul Shurtleff Hatch and Heidi Hatch Ford Scholar Award for Type 1 Diabetes Research.” See attached RFA for more details.
| |
|
|
3i Funding Opportunities
Current Federal and Private FOAs applicable to the 3is can be found on the U's pivot page. New FOAs announced this week:
A monthly funding newsletter from PIVOT is sent to 3i investigators on the 2nd Monday of the month. If you have not been receiving the newsletter and would like to be added, please email Nicole.Frank@hsc.utah.edu.
| |
|
3i Investigator PublicationsCongratulations to the teams who published this week. If you have a publication that you would like included, please email us.
| |
|
CONCLUSIONS: ICIs were not cost-effective as neoadjuvant therapies, except when atezolizumab was compared with ddMVAC. Randomized clinical trials, larger sample sizes and longer follow-up are required to better understand the value of ICIs as neoadjuvant treatments.
CONCLUSION: In this real-world study of PsA therapies with differing mechanisms of action, the IL-12/23i demonstrated longer persistence and higher adherence than either TNFis or tsDMARDs, and comparability to IL-17is.
OBJECTIVES: Patient-generated health data (PGHD) are clinically relevant data captured by patients outside of the traditional care setting. Clinical use of PGHD has emerged as an essential issue. This study explored the evidence to determine the extent of and describe the characteristics of PGHD integration into electronic health records (EHRs).
No abstract
CONCLUSION: UHb-DWI of the CSC reveals a marked difference in signal-b-curves and D(H) values in MS lesions compared to NAWM and healthy control WM. Based on physical principles, we interpret these altered observations of quantitative diffusion values to be indicative of demyelination. Further studies in animal models will be required to fully interpret UHb-DWI quantitative diffusion values during demyelination and remyelination.
Recent rapid Arctic sea-ice reduction has been well documented in observations, reconstructions and model simulations. However, the rate of sea ice loss is highly variable in both time and space. The western Arctic has seen the fastest sea-ice decline, with substantial interannual and decadal variability, but the underlying mechanism remains unclear. Here we demonstrate, through both observations and model simulations, that the Pacific North American (PNA) pattern is an important driver of...
There are no program evaluation approaches designed for a crisis, such as the COVID-19 pandemic. It is critical to evaluate the educational impact of COVID-19 to keep administrators informed and guide decision-making. The authors used systems thinking to design an evaluation model. The evaluation results suggest complex interactions between individuals and course level changes due to COVID-19. Specifically, year 1-2 students found more education metrics lacking relative to year 3-4 students,...
CONCLUSIONS: Clinical factors (e.g. older age, hematological malignancy, recent chemotherapy) and laboratory measurements were associated with poor outcomes among patients with cancer and COVID-19. Although further studies are needed, caution may be required in utilizing particular anti-cancer therapies.
CONCLUSIONS: Most children treated for CAP as outpatients are prescribed at least 10 days of antibiotic therapy. Among pediatric outpatients with CAP, no significant differences were found in rates of adverse clinical outcomes between patients prescribed short- versus prolonged-duration antibiotics.
BACKGROUND: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear.
| |
|
|
|
|
